2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in
Status
ACTIVE
Global HQ
Kowloon Bay, Hong Kong
Countries of investment
  • United States
  • China
Investment stages
  • Seed
  • Series A
  • Series B
  • Growth
Industries
  • Biotechnology
  • Life Sciences
  • Biologics
  • Pharma
  • MedTech
  • Medical Devices
  • Diagnostics
  • Digital Health
  • Health Tech
About
Aulis Capital is a Hong Kong-based healthcare investment firm, also operating from California, founded in 2025 by Nisa Leung after 19 years as a managing partner at Qiming Venture Partners. In November 2026 it announced the final close of its debut fund, Aulis Capital Fund I, L.P., with $200M of total commitments to invest in early and growth stage life sciences and healthcare companies across the East and West. Former McKinsey senior partner Franck Le Deu joined in 2026 as a venture partner to build its life sciences practice in China and Asia, alongside venture partners Lingshi Tan, Paul Li, Alwin Poon and Ethan Than. Its early investments include EpiBiologics, a San Mateo protein degradation company in whose $107M Series B, co-led by GV and Johnson & Johnson Innovation, Aulis participated in January 2026.
Min check size
$3M
Max check size
$15M
Fund size
NPS

Investment Thesis

Aulis Capital is a global healthcare investor backing early and growth stage companies in biotech, medical technology, medical devices, diagnostics and digital health. It partners with entrepreneurs building cross-border businesses that bridge Western and Asian life sciences, using China's scale, engineering and clinical development strengths to help companies reach global markets. Its edge is founder Nisa Leung's two decades building one of China's leading healthcare venture practices and a proprietary network of hospitals, academic institutions and healthcare companies in Asia and globally.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Nisa Leung joined Qiming Venture Partners in 2006, launched and led its healthcare practice as managing partner for 19 years until her departure in February 2025, overseeing about 220 startups with some 300 drug assets including Gan & Lee Pharmaceuticals, Zai Lab, CanSino Biologics and Insilico; earlier she co-founded Biomedic Holdings, whose Novamed and U-Systems were acquired by SciClone and GE Healthcare. Venture partner Franck Le Deu is a McKinsey senior partner emeritus who led its Greater China healthcare practice and co-led its Asia healthcare practice before founding KerZheng Ventures in 2025. Venture partner Lingshi Tan is executive chairman and former CEO of Caidya, founder of dMed Clinical, spent about 20 years at Pfizer and chaired the DIA Global Board.

Aulis Capital Contacts Information

Primary contact

Secondary contact

Team

Nisa Leung - Founding Managing Partner

Mingyu Xue - Principal

Grace Ng - Chief Financial Officer

Franck Le Deu - Venture Partner

Lingshi Tan - Venture Partner

Paul Li - Venture Partner

Alwin Poon - Venture Partner

Ethan Than - Venture Partner

Portfolio

EpiBiologics

Shyld AI

Fund number
Year Founded
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp